GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Moberg Pharma AB (OSTO:MOB) » Definitions » EPS (Diluted)

Moberg Pharma AB (OSTO:MOB) EPS (Diluted) : kr-1.08 (TTM As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Moberg Pharma AB EPS (Diluted)?

Moberg Pharma AB's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was kr-0.23. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was kr-1.08.

Moberg Pharma AB's EPS (Basic) for the three months ended in Mar. 2024 was kr-0.23. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was kr-1.08.

Moberg Pharma AB's EPS without NRI for the three months ended in Mar. 2024 was kr-0.23. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was kr-1.08.

During the past 3 years, the average EPS without NRIGrowth Rate was 41.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was -2.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Moberg Pharma AB's highest 3-Year average EPS without NRI Growth Rate was 61.90% per year. The lowest was -87.10% per year. And the median was 40.00% per year.


Moberg Pharma AB EPS (Diluted) Historical Data

The historical data trend for Moberg Pharma AB's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moberg Pharma AB EPS (Diluted) Chart

Moberg Pharma AB Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.49 -6.79 1.13 -2.07 -1.33

Moberg Pharma AB Quarterly Data
Mar19 Jun19 Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.51 -0.26 -0.36 -0.23 -0.23

Competitive Comparison of Moberg Pharma AB's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moberg Pharma AB's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's PE Ratio distribution charts can be found below:

* The bar in red indicates where Moberg Pharma AB's PE Ratio falls into.



Moberg Pharma AB EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Moberg Pharma AB's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-21.093-0)/35.521
=-0.59

Moberg Pharma AB's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-6.497-0)/47.611
=-0.14

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-1.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Moberg Pharma AB  (OSTO:MOB) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Moberg Pharma AB EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Moberg Pharma AB's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Moberg Pharma AB (OSTO:MOB) Business Description

Traded in Other Exchanges
Address
Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Moberg Pharma has commercial agreements with partners in Europe and Canada, among others.